Drugs / Flotetuzumab
Trials 8 · a red edge is where a trial was stopped
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Flotetuzumab | “This phase II trial studies how well flotetuzumab works in treating patients with CD123 positive blood cancer that has come back or does not respond to treatment.” NCT03739606 ↗ |
| Known as | MGD-006 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990038 ↗ |
| Known as | NSC#808294 | “A Phase 1 Trial of the CD123 X CD3 DART Molecule Flotetuzumab (NSC#808294) in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia” NCT04158739 ↗ |
| Known as | RES-234 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990038 ↗ |
| Known as | S-80880 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990038 ↗ |
| Modality | Monoclonal antibody | “Immunotherapy with monoclonal antibodies, such as flotetuzumab, may help the body's immune system attack the cancer” NCT03739606 ↗ |
| Route | Intravenous | “Given IV” NCT03739606 ↗ |
| Target | IL3RA | “Interleukin-3 receptor subunit alpha binding agent” CHEMBL3990038 ↗ |